{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:56:00Z","timestamp":1782143760557,"version":"3.54.5"},"reference-count":59,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jiac.2019.03.015","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T11:52:51Z","timestamp":1554983571000},"page":"687-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A model-based comparative meta-analysis of the efficacy of dolutegravir-based and efavirenz-based regimens in HIV-infected patients"],"prefix":"10.1016","volume":"25","author":[{"given":"Ryosaku","family":"Ota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3503-8696","authenticated-orcid":false,"given":"Fumiyoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2019.03.015_bib1","series-title":"UNAIDS DATA","author":"UNAIDS","year":"2018"},{"key":"10.1016\/j.jiac.2019.03.015_bib2","article-title":"Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2019.03.015_bib3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/jac\/dkp334","article-title":"Efavirenz: a decade of clinical experience in the treatment of HIV","volume":"64","author":"Maggiolo","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2019.03.015_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1060028013513558","article-title":"Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection","volume":"48","author":"Rathbun","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jiac.2019.03.015_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/phar.1386","article-title":"Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV","volume":"34","author":"Shah","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2019.03.015_bib6","author":"The Department of Health and Human Services"},{"key":"10.1016\/j.jiac.2019.03.015_bib7","series-title":"The European guidelines for treatment of HIV infected adults in Europe","author":"European AIDS Clinical Society","year":"2015"},{"key":"10.1016\/j.jiac.2019.03.015_bib8","unstructured":"Clinton Health Access Initiative. reportHIV Market Report. https:\/\/clintonhealthaccess.org\/content\/uploads\/2018\/09\/2018-HIV-Market-Report_FINAL.pdf [accessed 9 February 2019]."},{"key":"10.1016\/j.jiac.2019.03.015_bib9","author":"World Health Organization"},{"key":"10.1016\/j.jiac.2019.03.015_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162775","article-title":"Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: a systematic review","volume":"11","author":"Rutherford","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2019.03.015_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105653","article-title":"48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis","volume":"9","author":"Patel","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2019.03.015_bib12","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","article-title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis","volume":"3","author":"Kanters","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2019.03.015_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/clpt.2012.122","article-title":"Model-based meta-analysis: an important tool for making quantitative decisions during drug development","volume":"92","author":"Mould","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2019.03.015_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001844","article-title":"A\u00a0novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus","volume":"3","author":"Gross","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jiac.2019.03.015_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jiac.2019.03.015_bib16","series-title":"Cochrane Handbook for systematic reviews of interventions","year":"2011"},{"key":"10.1016\/j.jiac.2019.03.015_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124279","article-title":"Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Kryst","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2019.03.015_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib19","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir\u2013Lamivudine versus tenofovir\u2013emtricitabine for initial HIV-1 therapy","volume":"361","author":"Sax","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2019.03.015_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2169\/internalmedicine.50.4572","article-title":"Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine","volume":"50","author":"Honda","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.jiac.2019.03.015_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.antiviral.2009.11.008","article-title":"Similar antiviral efficacy and tolerability between efavirenz and lopinavir\/ritonavir, administered with abacavir\/lamivudine (Kivexa), in antiretroviral-naive patients: a 48-week, multicentre, randomized study (Lake Study)","volume":"85","author":"Echeverria","year":"2010","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiac.2019.03.015_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAI.0b013e3181dd911e","article-title":"Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir\/lamivudine versus tenofovir\/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study","volume":"55","author":"Post","year":"2010","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/1471-2334-13-269","article-title":"Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir\/ritonavir vs. efavirenz with abacavir\/lamivudine in underrepresented, antiretroviral-naive, HIV-infected patients (SUPPORT): 96-week results","volume":"13","author":"Kumar","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2019.03.015_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/01.qai.0000243092.40490.26","article-title":"Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir\/Ritonavir, or Stavudine","volume":"43","author":"Bartlett","year":"2006","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.qai.0000147521.34369.c9","article-title":"Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen once Daily in Antiretroviral Combination Study","volume":"38","author":"Moyle","year":"2005","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/424009","article-title":"Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults","volume":"39","author":"DeJesus","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2019.03.015_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib28","first-page":"36","article-title":"Safety and antiviral effect of Elpida (VM-1500), a novel NNRTI (+Truvada) in treatment-naive HIV-1-infected patients at 24- to 48-week therapy","volume":"19","author":"Kravchenko","year":"2016","journal-title":"J\u00a0Int AIDS Soc"},{"key":"10.1016\/j.jiac.2019.03.015_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31815acab8","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine\/lamivudine and efavirenz in treatment-naive patients: 144-week analysis","volume":"47","author":"Arribas","year":"2008","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK","volume":"63","author":"Rockstroh","year":"2013","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jiac.2019.03.015_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3851\/IMP2675","article-title":"Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial","volume":"19","author":"Landman","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jiac.2019.03.015_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/QAI.0b013e31827a2ba2.","article-title":"Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial","volume":"62","author":"Vernazza","year":"2013","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib34","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"Cohen","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2019.03.015_bib35","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","author":"ENCORE1 Study Group","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jiac.2019.03.015_bib36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study","volume":"15","author":"ENCORE1 Study Group","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2019.03.015_bib37","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2019.03.015_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/QAD.0000000000000911","article-title":"Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study","volume":"30","author":"van Lunzen","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2019.03.015_bib39","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/QAD.0000000000000988","article-title":"A\u00a048-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus","volume":"30","author":"Thompson","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2019.03.015_bib40","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/QAI.0000000000000567","article-title":"Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1-Infected patients starting efavirenz, lopinavir-ritonavir, or atazanavir-ritonavir plus tenofovir\/emtricitabine: final 48-week results (the advanz-3 trial)","volume":"69","author":"Miro","year":"2015","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib41","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1086\/656363","article-title":"Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study","volume":"51","author":"Puls","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2019.03.015_bib42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0b013e3181b064b0","article-title":"Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection","volume":"52","author":"Markowitz","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib43","series-title":"Elvucitabine\/Efavirenz\/Tenofovir vs. Lamivudine\/Efavirenz\/Tenofovir in HIV-1 infected, treatment naive subjects","year":"2016"},{"key":"10.1016\/j.jiac.2019.03.015_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jiac.2019.03.015_bib45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jiac.2019.03.015_bib46","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2019.03.015_bib47","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jiac.2019.03.015_bib48","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2352-3018(17)30095-4","article-title":"Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label","volume":"4","author":"Orrell","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2019.03.015_bib49","author":"World Health Organization"},{"key":"10.1016\/j.jiac.2019.03.015_bib50","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11538-016-0145-5","article-title":"Dynamics of an HIV model with multiple infection stages and treatment with different drug classes","volume":"78","author":"Wang","year":"2016","journal-title":"Bull Math Biol"},{"key":"10.1016\/j.jiac.2019.03.015_bib51","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/AAC.01537-09","article-title":"Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture","volume":"54","author":"Donahue","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.03.015_bib52","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jir636","article-title":"Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir","volume":"204","author":"Canducci","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2019.03.015_bib53","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2019.03.015_bib54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2008.01.002","article-title":"Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors","volume":"134","author":"Sluis-Cremer","year":"2008","journal-title":"Virus Res"},{"key":"10.1016\/j.jiac.2019.03.015_bib55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00126334-200112010-00002","article-title":"Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy","volume":"28","author":"Skowron","year":"2001","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2019.03.015_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0895-4356(01)00414-0","article-title":"A\u00a0comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis","volume":"55","author":"Lambert","year":"2002","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jiac.2019.03.015_bib57","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/aje\/kwn179","article-title":"Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women","volume":"168","author":"Jarrin","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jiac.2019.03.015_bib58","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000236338.41799.57","article-title":"Pharmacogenetics of HIV therapy","volume":"16","author":"Owen","year":"2006","journal-title":"Pharmacogenetics Genom"},{"key":"10.1016\/j.jiac.2019.03.015_bib59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00228-013-1634-1","article-title":"Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz","volume":"70","author":"Naidoo","year":"2014","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19300790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19300790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:58:58Z","timestamp":1761159538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X19300790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1341321X19300790"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2019.03.015","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A model-based comparative meta-analysis of the efficacy of dolutegravir-based and efavirenz-based regimens in HIV-infected patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2019.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}